Transformer 2β regulates the alternative splicing of cell cycle regulatory genes to promote the malignant phenotype of ovarian cancer.
CYR61
HMGA2
Ovarian cancer
RNA binding proteins
Splicing
TRA2B
Journal
Oncology research
ISSN: 1555-3906
Titre abrégé: Oncol Res
Pays: United States
ID NLM: 9208097
Informations de publication
Date de publication:
2023
2023
Historique:
received:
24
03
2023
accepted:
18
05
2023
medline:
8
8
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
epublish
Résumé
Late-stage ovarian cancer (OC) has a poor prognosis and a high metastasis rate, but the underlying molecular mechanism is unclear. RNA binding proteins (RBPs) play important roles in posttranscriptional regulation in the contexts of neoplasia and tumor metastasis. In this study, we explored the molecular functions of a canonical RBP, Transformer 2β homolog (TRA2B), in cancer cells. TRA2B knockdown in HeLa cells and subsequent whole-transcriptome RNA sequencing (RNA-seq) analysis revealed the TRA2B-regulated alternative splicing (AS) profile. We disrupted TRA2B expression in epithelial OC cells and performed a series of experiments to confirm the resulting effects on OC cell proliferation, apoptosis and invasion. TRA2B-regulated AS was tightly associated with the mitotic cell cycle, apoptosis and several cancer pathways. Moreover, the expression of hundreds of genes was regulated by TRA2B, and these genes were enriched in the functions of cell proliferation, cell adhesion and angiogenesis, which are related to the malignant phenotype of OC. By integrating the alternatively spliced and differentially expressed genes, we found that AS events and gene expression were regulated independently. We then explored and validated the oncogenic functions of TRA2B by knocking down its expression in OC cells. The high TRA2B expression was associated with poor prognosis in patients with OC. In ovarian tissue, TRA2B expression showed a gradual increasing trend with increasing malignancy. We demonstrated the important roles of TRA2B in ovarian neoplasia and aggressive OC behaviors and identified the underlying molecular mechanisms, facilitating the targeted treatment of OC.
Identifiants
pubmed: 37547760
doi: 10.32604/or.2023.030166
pii: 30166
pmc: PMC10398401
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
769-785Informations de copyright
© 2023 Zhou et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest to report regarding the present study.
Références
Oncol Lett. 2019 Sep;18(3):2455-2463
pubmed: 31452736
Semin Cancer Biol. 2022 Nov;86(Pt 2):748-768
pubmed: 35339667
Hum Mol Genet. 2005 Aug 15;14(16):2289-303
pubmed: 16000324
Oncol Rep. 2004 May;11(5):1085-90
pubmed: 15069551
Genomics. 1998 Oct 15;53(2):191-202
pubmed: 9790768
J Virol. 2017 Jun 26;91(14):
pubmed: 28446664
Cells. 2021 Dec 15;10(12):
pubmed: 34944051
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Clin Cancer Res. 2004 Mar 15;10(6):2072-81
pubmed: 15041728
J Virol. 2013 Mar;87(5):2721-34
pubmed: 23255807
Hum Mol Genet. 2011 Jun 15;20(12):2356-65
pubmed: 21447598
Biochim Biophys Acta Gene Regul Mech. 2017 Sep;1860(9):911-921
pubmed: 28733224
Oncogenesis. 2016 Apr 04;5:e213
pubmed: 27043659
Trends Cancer. 2017 Jul;3(7):506-528
pubmed: 28718405
Am J Pathol. 2004 May;164(5):1511-8
pubmed: 15111296
Genetics. 2012 Nov;192(3):1015-26
pubmed: 22942126
Nat Biotechnol. 2019 Mar;37(3):314-322
pubmed: 30778230
Nat Commun. 2014 Sep 11;5:4760
pubmed: 25208576
Clin Cancer Res. 2008 Sep 1;14(17):5494-502
pubmed: 18765541
Cell. 2019 Jun 27;178(1):107-121.e18
pubmed: 31251911
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Biochem Biophys Res Commun. 2018 Jan 1;495(1):1528-1533
pubmed: 29203241
Nat Biotechnol. 2010 May;28(5):511-5
pubmed: 20436464
Lancet. 2014 Oct 11;384(9951):1376-88
pubmed: 24767708
Int J Cell Biol. 2013;2013:843781
pubmed: 23935626
BMC Genomics. 2017 Feb 6;18(1):130
pubmed: 28166730
Am J Physiol Cell Physiol. 2015 Feb 15;308(4):C289-96
pubmed: 25428883
Nucleic Acids Res. 2011 Jul;39(Web Server issue):W316-22
pubmed: 21715386
Curr Opin Genet Dev. 2010 Aug;20(4):376-83
pubmed: 20570131
PLoS Genet. 2011 Dec;7(12):e1002390
pubmed: 22194695
Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9004-9
pubmed: 8799144
J Biol Chem. 2015 Jul 10;290(28):17269-81
pubmed: 26013829
J Biol Chem. 2013 Mar 29;288(13):8898-909
pubmed: 23396973
Nat Rev Genet. 2014 Dec;15(12):829-45
pubmed: 25365966
Insect Biochem Mol Biol. 2013 Dec;43(12):1125-32
pubmed: 24056158
Genome Biol. 2010;11(10):R106
pubmed: 20979621
Nat Rev Cancer. 2002 Apr;2(4):315-9
pubmed: 12001993
Endocr Relat Cancer. 2012 Apr 10;19(2):197-208
pubmed: 22277193
J Biol Chem. 2014 Nov 14;289(46):31662-31672
pubmed: 25261467
Insect Biochem Mol Biol. 2019 Jun;109:92-105
pubmed: 30914323
Genes (Basel). 2022 Feb 24;13(3):
pubmed: 35327956
Cell Rep. 2017 Aug 29;20(9):2215-2226
pubmed: 28854369
Genes Dev. 2012 May 1;26(9):877-90
pubmed: 22549953
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Cancer Res. 2006 May 1;66(9):4774-80
pubmed: 16651431
Cell Death Differ. 2015 May;22(5):815-25
pubmed: 25342468
Genome Biol. 2013 Apr 25;14(4):R36
pubmed: 23618408
Exp Oncol. 2010 Mar;32(1):2-9
pubmed: 20332765
Mol Cell. 2019 Feb 21;73(4):775-787.e10
pubmed: 30642763
Nat Rev Mol Cell Biol. 2018 May;19(5):327-341
pubmed: 29339797